{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T10:46:32Z","timestamp":1788173192294,"version":"build-2803163510"},"reference-count":38,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2024,1,4]],"date-time":"2024-01-04T00:00:00Z","timestamp":1704326400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Innovative Medicines Initiative 2 Joint Undertaking","award":["853966"],"award-info":[{"award-number":["853966"]}]},{"DOI":"10.13039\/501100000780","name":"European Union","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"name":"EFPIA and Children\u2019s Tumor Foundation"},{"name":"Global Alliance for TB Drug Development"},{"DOI":"10.13039\/100020337","name":"SpringWorks Therapeutics Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020337","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,7,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Neurofibromatosis type 1, NF2-related schwannomatosis and non-NF2-related schwannomatosis (grouped under the abbreviation \u201cNF\u201d) are rare hereditary tumor predisposition syndromes. Due to the low prevalence, variability in the range, and severity of manifestations, as well as limited treatment options, these conditions require innovative trial designs to accelerate the development of new treatments.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Within European Patient-Centric Clinical Trial Platforms (EU-PEARL), we designed 2 platform-basket trials in NF. The trials were designed by a team of multidisciplinary NF experts and trial methodology experts.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The trial will consist of an observational and a treatment period. The observational period will serve as a longitudinal natural history study. The platform trial design and randomization to a sequence of available interventions allow for the addition of interventions during the trial. If a drug does not meet the predetermined efficacy endpoint or reveals unacceptable toxicities, participants may stop treatment on that arm and re-enter the observational period, where they can be re-randomized to a different treatment arm if eligible. Intervention-specific eligibility criteria and endpoints are listed in intervention-specific-appendices, allowing the flexibility and adaptability needed for highly variable and rare conditions like NF.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>These innovative platform-basket trials for NF may serve as a model for other rare diseases, as they will enhance the chance of identifying beneficial treatments through optimal learning from a small number of patients. The goal of these trials is to identify beneficial treatments for NF more rapidly and at a lower cost than traditional, single-agent clinical trials.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/nop\/npae001","type":"journal-article","created":{"date-parts":[[2024,1,4]],"date-time":"2024-01-04T09:02:15Z","timestamp":1704358935000},"page":"395-403","source":"Crossref","is-referenced-by-count":8,"title":["Platform trial design for neurofibromatosis type 1, NF2-related schwannomatosis and non-NF2-related schwannomatosis: A potential model for rare diseases"],"prefix":"10.1093","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0928-4049","authenticated-orcid":false,"given":"Britt A E","family":"Dhaenens","sequence":"first","affiliation":[{"name":"Department of General Paediatrics, Erasmus MC-Sophia Children\u2019s Hospital , Rotterdam , The Netherlands"},{"name":"ENCORE Expertise Centre for Neurodevelopmental Disorders, Erasmus MC , Rotterdam , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00fcnter","family":"Heimann","sequence":"additional","affiliation":[{"name":"Biostatistics & Pharmacometrics, Novartis Pharma AG , Basel , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette","family":"Bakker","sequence":"additional","affiliation":[{"name":"Children\u2019s Tumor Foundation , New York, New York , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Nievo","sequence":"additional","affiliation":[{"name":"Children\u2019s Tumor Foundation , New York, New York , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosalie E","family":"Ferner","sequence":"additional","affiliation":[{"name":"Neurofibromatosis Service, Department of Neurology, Guy\u2019s and St. Thomas\u2019 NHS Foundation Trust London , Great Maze Pond, London , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D Gareth","family":"Evans","sequence":"additional","affiliation":[{"name":"Centre for Genomic Medicine, Division of Evolution, Infection and Genomic Sciences, University of Manchester, St Mary\u2019s Hospital , Manchester , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Wolkenstein","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Henri-Mondor Hospital , Cr\u00e9teil , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas","family":"Leubner","sequence":"additional","affiliation":[{"name":"Department of Pediatric Neurology, Charit\u00e9 Universit\u00e4tsmedizin Berlin\u2014Universit\u00e4tsmedizin Berlin, corporate member of Freie Universit\u00e4t Berlin and Humboldt Universit\u00e4t zu Berlin , Berlin , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelia","family":"Potratz","sequence":"additional","affiliation":[{"name":"Department of Pediatric Neurology, Charit\u00e9 Universit\u00e4tsmedizin Berlin\u2014Universit\u00e4tsmedizin Berlin, corporate member of Freie Universit\u00e4t Berlin and Humboldt Universit\u00e4t zu Berlin , Berlin , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Carton","sequence":"additional","affiliation":[{"name":"Department of Human Genetics, KU Leuven , Leuven , Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uchenna","family":"Iloeje","sequence":"additional","affiliation":[{"name":"Medical Affairs, SpringWorks Therapeutics , Stamford, Connecticut , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Kirk","sequence":"additional","affiliation":[{"name":"AstraZeneca Oncology R&D , Cambridge , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaishri O","family":"Blakeley","sequence":"additional","affiliation":[{"name":"Department of Neurology, Neuro-Oncology, Johns Hopkins University School of Medicine , Baltimore, Maryland , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Plotkin","sequence":"additional","affiliation":[{"name":"Cancer Center and Department of Neurology, Massachusetts General Hospital , Boston, Massachusetts , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J","family":"Fisher","sequence":"additional","affiliation":[{"name":"Division of Oncology, Children\u2019s Hospital of Philadelphia , Philadelphia, Pennsylvania , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7813-5568","authenticated-orcid":false,"given":"AeRang","family":"Kim","sequence":"additional","affiliation":[{"name":"Division of Oncology, Children\u2019s National Hospital , Washington DC, District of Columbia , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3135-3872","authenticated-orcid":false,"given":"Pablo Hern\u00e1iz","family":"Driever","sequence":"additional","affiliation":[{"name":"Charit\u00e9\u2014Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin and Humboldt Universit\u00e4t zu Berlin , Berlin , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amedeo A","family":"Azizi","sequence":"additional","affiliation":[{"name":"Division of Neonatology, Pediatric Intensive Care and Neuropediatrics, Department of Pediatrics and Adolescent Medicine, Medical University of Vienna , Wien , Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigitte C","family":"Widemann","sequence":"additional","affiliation":[{"name":"Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute , Bethesda, Maryland , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1646-4531","authenticated-orcid":false,"given":"Andrea","family":"Gross","sequence":"additional","affiliation":[{"name":"Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute , Bethesda, Maryland , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Parke","sequence":"additional","affiliation":[{"name":"Berry Consultants , Abingdon , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Legius","sequence":"additional","affiliation":[{"name":"Department of Human Genetics, KU Leuven , Leuven , Belgium"},{"name":"Department of Clinical Genetics, UZ Leuven , Leuven , Belgium"},{"name":"Full Member of the European Reference Network on Genetic Tumour Risk Syndromes (ERN GENTURIS) , Nijmegen , The Netherlands (E.L., R.O.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rianne","family":"Oostenbrink","sequence":"additional","affiliation":[{"name":"Department of General Paediatrics, Erasmus MC-Sophia Children\u2019s Hospital , Rotterdam , The Netherlands"},{"name":"ENCORE Expertise Centre for Neurodevelopmental Disorders, Erasmus MC , Rotterdam , The Netherlands"},{"name":"Full Member of the European Reference Network on Genetic Tumour Risk Syndromes (ERN GENTURIS) , Nijmegen , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,1,4]]},"reference":[{"issue":"3","key":"2024071213311945100_CIT0001","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/jid.2014.465","article-title":"Incidence and mortality of neurofibromatosis: a total population study in Finland","volume":"135","author":"Uusitalo","year":"2015","journal-title":"J Invest Dermatol."},{"issue":"2","key":"2024071213311945100_CIT0002","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1002\/ajmg.a.33139","article-title":"Birth incidence and prevalence of tumor-prone syndromes: estimates from a UK family genetic register service","volume":"152A","author":"Evans","year":"2010","journal-title":"Am J Med Genet A."},{"issue":"11","key":"2024071213311945100_CIT0003","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1136\/jnnp-2018-318538","article-title":"Schwannomatosis: a genetic and epidemiological study","volume":"89","author":"Evans","year":"2018","journal-title":"J Neurol Neurosurg Psychiatry."},{"issue":"2","key":"2024071213311945100_CIT0004","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1136\/jnnp.2010.206532","article-title":"The neurofibromatoses","volume":"10","author":"Ferner","year":"2010","journal-title":"Pract Neurol."},{"key":"2024071213311945100_CIT0005","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/B978-0-444-52891-9.00039-7","article-title":"Neurofibromatosis","volume":"111","author":"Korf BR","year":"2013","journal-title":"Handb Clin Neurol"},{"issue":"5","key":"2024071213311945100_CIT0006","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1080\/14728222.2018.1465931","article-title":"Emerging therapeutic targets for neurofibromatosis type 1","volume":"22","author":"Walker","year":"2018","journal-title":"Expert Opin Ther Targets."},{"issue":"11","key":"2024071213311945100_CIT0007","doi-asserted-by":"crossref","first-page":"5850","DOI":"10.3390\/ijms22115850","article-title":"Current understanding of neurofibromatosis type 1, 2, and schwannomatosis","volume":"22","author":"Tamura","year":"2021","journal-title":"Int J Mol Sci."},{"issue":"9","key":"2024071213311945100_CIT0008","doi-asserted-by":"crossref","first-page":"104281","DOI":"10.1016\/j.ejmg.2021.104281","article-title":"Lessons learned from drug trials in neurofibromatosis: a systematic review","volume":"64","author":"Dhaenens","year":"2021","journal-title":"Eur J Med Genet."},{"issue":"5","key":"2024071213311945100_CIT0009","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1093\/neuonc\/nov200","article-title":"Therapeutic advances for the tumors associated with neurofibromatosis type 1, type 2, and schwannomatosis","volume":"18","author":"Blakeley","year":"2016","journal-title":"Neuro Oncol"},{"issue":"4","key":"2024071213311945100_CIT0010","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1002\/ajmg.a.38413","article-title":"Challenges of developing and conducting clinical trials in rare disorders","volume":"176","author":"Kempf","year":"2018","journal-title":"Am J Med Genet A."},{"key":"2024071213311945100_CIT0011","volume-title":"Rare Diseases: Natural History Studies for Drug Development Guidance for Industry\u2014Draft Guidance","author":"U.S. Department of Health and Human Services, Center for Biologics Evaluation and Research (CBER), Office of Orphan Products Development (OOPD)","year":"2019"},{"key":"2024071213311945100_CIT0012"},{"issue":"10","key":"2024071213311945100_CIT0013","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1038\/s41573-019-0034-3","article-title":"Adaptive platform trials: definition, design, conduct and reporting considerations","volume":"18","author":"Adaptive Platform Trials","year":"2019","journal-title":"Nat Rev Drug Discov."},{"issue":"2","key":"2024071213311945100_CIT0014","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1002\/ana.26285","article-title":"Adaptive platform trials to transform amyotrophic lateral sclerosis therapy development","volume":"91","author":"Paganoni","year":"2022","journal-title":"Ann Neurol."},{"issue":"22","key":"2024071213311945100_CIT0015","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1001\/jama.2012.4174","article-title":"Adaptive clinical trials: a partial remedy for the therapeutic misconception","volume":"307","author":"Meurer","year":"2012","journal-title":"JAMA."},{"issue":"4","key":"2024071213311945100_CIT0016","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1158\/1078-0432.CCR-17-0764","article-title":"Adaptive global innovative learning environment for glioblastoma: GBM AGILE","volume":"24","author":"Alexander","year":"2018","journal-title":"Clin Cancer Res."},{"issue":"6","key":"2024071213311945100_CIT0017","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1002\/cpt.814","article-title":"Critical review of umbrella, basket, and platform designs for oncology clinical trials","volume":"102","author":"Simon","year":"2017","journal-title":"Clin Pharmacol Ther."},{"issue":"8","key":"2024071213311945100_CIT0018","doi-asserted-by":"crossref","first-page":"e021944","DOI":"10.1136\/bmjopen-2018-021944","article-title":"Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial (MS-SMART): a multiarm phase IIb randomised, double-blind, placebo-controlled clinical trial comparing the efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis","volume":"8","author":"Connick","year":"2018","journal-title":"BMJ Open."},{"issue":"1","key":"2024071213311945100_CIT0019","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jalz.2016.07.005","article-title":"The DIAN-TU next generation Alzheimer\u2019s prevention trial: adaptive design and disease progression model","volume":"13","author":"Bateman","year":"2017","journal-title":"Alzheimers Dement"},{"key":"2024071213311945100_CIT0020","doi-asserted-by":"crossref","first-page":"106625","DOI":"10.1016\/j.cct.2021.106625","article-title":"Implementation of platform trials in the COVID-19 pandemic: a rapid review","volume":"112","author":"Vanderbeek","year":"2022","journal-title":"Contemp Clin Trials."},{"issue":"3","key":"2024071213311945100_CIT0021","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1177\/1740774515626362","article-title":"Efficiencies of platform clinical trials: a vision of the future","volume":"13","author":"Saville","year":"2016","journal-title":"Clin Trials."},{"issue":"7","key":"2024071213311945100_CIT0022","doi-asserted-by":"crossref","first-page":"e2221140","DOI":"10.1001\/jamanetworkopen.2022.21140","article-title":"Economic evaluation of cost and time required for a platform trial vs conventional trials","volume":"5","author":"Park","year":"2022","journal-title":"JAMA Netw Open."},{"key":"2024071213311945100_CIT0023","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1186\/1745-6215-13-168","article-title":"Flexible trial design in practice\u2014stopping arms for lack-of-benefit and adding research arms mid-trial in STAMPEDE: a multi-arm multi-stage randomized controlled trial","volume":"13","author":"Sydes","year":"2012","journal-title":"Trials."},{"issue":"4","key":"2024071213311945100_CIT0024","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s12609-019-00334-2","article-title":"I-SPY 2: A neoadjuvant adaptive clinical trial designed to improve outcomes in high-risk breast cancer","volume":"11","author":"Wang","year":"2019","journal-title":"Curr Breast Cancer Rep"},{"issue":"1","key":"2024071213311945100_CIT0025","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1056\/NEJMra1510062","article-title":"Master protocols to study multiple therapies, multiple diseases, or both","volume":"377","author":"Woodcock","year":"2017","journal-title":"N Engl J Med."},{"key":"2024071213311945100_CIT0026","author":"ClinicalTrials.gov","year":"2023"},{"key":"2024071213311945100_CIT0027","year":"2021"},{"issue":"11","key":"2024071213311945100_CIT0028","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1038\/s41431-021-00892-z","article-title":"Identifying challenges in neurofibromatosis: a modified Delphi procedure","volume":"29","author":"Dhaenens","year":"2021","journal-title":"Eur J Hum Genet."},{"issue":"1","key":"2024071213311945100_CIT0029","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/insr.12000","article-title":"Confidence distribution, the frequentist distribution estimator of a parameter: A review","volume":"81","author":"Xie","year":"2013","journal-title":"Int Stat Rev."},{"issue":"15","key":"2024071213311945100_CIT0030","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1912735","article-title":"Selumetinib in children with inoperable plexiform neurofibromas","volume":"382","author":"Gross","year":"2020","journal-title":"N Engl J Med."},{"issue":"35","key":"2024071213311945100_CIT0031","doi-asserted-by":"crossref","first-page":"3446","DOI":"10.1200\/JCO.19.01367","article-title":"Multicenter, prospective, phase ii and biomarker study of high-dose bevacizumab as induction therapy in patients with neurofibromatosis type 2 and progressive vestibular schwannoma","volume":"37","author":"Plotkin","year":"2019","journal-title":"J Clin Oncol."},{"issue":"1","key":"2024071213311945100_CIT0032","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/s41591-020-01193-6","article-title":"Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial","volume":"27","author":"Fisher","year":"2021","journal-title":"Nat Med."},{"issue":"Supplement_5","key":"2024071213311945100_CIT0033","first-page":"96","article-title":"CTNI-80 INTUITT-NF2, An adaptive platform-basket trial for NF2-related schwannomatosis patients with progressive schwannomas, meningiomas, and ependymomas: Primary outcome of the brigatinib treatment arm","volume":"25","author":"Plotkin","year":"2023","journal-title":"Neuro Oncol"},{"key":"2024071213311945100_CIT0034","article-title":"Guidance for Industry: E10 choice of control group and related issues in clinical trials","author":"Food and Drug Administration (FDA)","year":"2001"},{"issue":"1","key":"2024071213311945100_CIT0035","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s12955-017-0607-y","article-title":"Evaluation of quality of life in adults with neurofibromatosis 1 (NF1) using the Impact of NF1 on Quality Of Life (INF1-QOL) questionnaire","volume":"15","author":"Ferner","year":"2017","journal-title":"Health Qual Life Outcomes."},{"issue":"2","key":"2024071213311945100_CIT0036","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.jhep.2022.09.021","article-title":"Platform trials to overcome major shortcomings of traditional clinical trials in non-alcoholic steatohepatitis? Pros and cons","volume":"78","author":"Peric\u00e0s","year":"2023","journal-title":"J Hepatol."},{"issue":"1-2","key":"2024071213311945100_CIT0037","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jns.2011.10.004","article-title":"Implementing clinical trials on an international platform: challenges and perspectives","volume":"313","author":"Minisman","year":"2012","journal-title":"J Neurol Sci."},{"issue":"8","key":"2024071213311945100_CIT0038","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1111\/cts.13547","article-title":"Optimizing expert and patient input in pediatric trial design: Lessons learned and recommendations from a collaboration between conect4children and European Patient-CEntric ClinicAl TRial PLatforms","volume":"16","author":"Dhaenens","year":"2023","journal-title":"Clin Transl Sci."}],"container-title":["Neuro-Oncology Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/nop\/advance-article-pdf\/doi\/10.1093\/nop\/npae001\/56454995\/npae001.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/nop\/article-pdf\/11\/4\/395\/58524227\/npae001.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/nop\/article-pdf\/11\/4\/395\/58524227\/npae001.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,12]],"date-time":"2024-07-12T15:15:47Z","timestamp":1720797347000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/nop\/article\/11\/4\/395\/7510576"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,4]]},"references-count":38,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,1,4]]},"published-print":{"date-parts":[[2024,7,12]]}},"URL":"https:\/\/doi.org\/10.1093\/nop\/npae001","relation":{},"ISSN":["2054-2577","2054-2585"],"issn-type":[{"value":"2054-2577","type":"print"},{"value":"2054-2585","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,8]]},"published":{"date-parts":[[2024,1,4]]}}}